Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.37 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.37 |
| ▸ | PSMD12 | O00232 | 1/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.37 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.37 |
| ▸ | PSMD3 | O43242 | 1/20 | 0.37 |
| ▸ | PSMC3 | P17980 | 1/20 | 0.37 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.37 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.37 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.37 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.37 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.37 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.37 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6895506 | 1.00 | CTSB (0.45) | CTSBLMNAPKMMAOBPSMB11 | |
| SCHEMBL6898261 | 0.88 | CYP3A4 (0.46) | CTSBLMNAPKM | |
| SCHEMBL6898138 | 0.88 | CYP3A4 (0.46) | CTSBLMNAPKM | |
| SCHEMBL27495255 | 0.87 | CTSB (0.50) | CTSBMAOB | |
| SCHEMBL6736905 | 0.87 | CTSB (0.50) | CTSBMAOB | |
| SCHEMBL6897256 | 0.83 | MME (0.38) | CTSBLMNAPKM | |
| SCHEMBL6897114 | 0.83 | MME (0.38) | CTSBLMNAPKM | |
| SCHEMBL7684657 | 0.83 | MME (0.38) | CTSBLMNAPKM | |
| SCHEMBL6741605 | 0.81 | CTSS (0.46) | CTSB | |
| SCHEMBL6737016 | 0.77 | CTSB (0.44) | CTSBMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | CTSB 1387/4885LMNA 4204/4885PKM 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.